Pfizer Inc. stock falls 1.16 percent amid market downturn and competitor gains

7 articles · Updated · MarketWatch · Apr 28

Pfizer shares closed at $26.48 on Tuesday, underperforming as Johnson & Johnson, Eli Lilly, and Abbott Laboratories all posted gains.
This marks Pfizer's second consecutive day of losses, with the stock now 7.88% below its 52-week high reached on April 2.
Trading volume surged to 56 million, significantly above the 50-day average, reflecting heightened investor activity during a broadly negative session for major US indices.

Why did investors punish Pfizer's stock after it announced a multi-billion dollar drug patent win?

Is Pfizer's 6.5% dividend a golden opportunity or a dangerous trap for income investors?

Can the massive Seagen acquisition save Pfizer from its fast-approaching patent cliff?

Will Pfizer's late entry into the obesity market be enough to challenge established leaders?

How will new government price controls impact funding for the next generation of life-saving drugs?